Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges.
Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges.
复制标题
DOI：
10.1186/s13024-016-0115-2
复制
发表时间：
2016-06-30
影响因子：
15.1
通讯作者：
Lemere CA
中科院分区：
文献类型：
--
作者：
Cynis H;Frost JL;Crehan H;Lemere CA
Immunization against amyloid-β (Aβ) peptides deposited in Alzheimer’s disease (AD) has shown considerable therapeutic effect in animal models however, the translation into human Alzheimer’s patients is challenging. In recent years, a number of promising Aβ immunotherapy trials failed to reach primary study endpoints. Aside from uncertainties in the selection of patients and the start and duration of treatment, these results also suggest that the mechanisms underlying AD are still not fully understood. Thorough characterizations of protein aggregates in AD brain have revealed a conspicuous heterogeneity of Aβ peptides enabling the study of the toxic potential of each of the major forms. One such form, amino-terminally truncated and modified pyroglutamate (pGlu)-3 Aβ peptide appears to play a seminal role for disease initiation, qualifying it as novel target for immunotherapy approaches.
